2026 marks a new development stage for tubular multi-effect distilled water machines, fueled by policy upgrades, technological innovation and global market expansion. The newly enforced GMP sterile appendix raises pharmaceutical water system compliance standards, mandating real-time endotoxin and TOC monitoring and prioritizing distillation technology for injection water preparation, driving large-scale replacement of old equipment. May’s new medical device export regulations optimize approval processes for compliant equipment, opening a "export first, register later" channel for domestic manufacturers and lowering overseas entry barriers.
Domestically, domestic equipment holds 78.4% of the market share, with 8+ effect high-efficiency models accounting for 63.7% of the high-end segment. The industry forms a differentiated regional layout: the east leads high-end development, the central accelerates large-scale deployment, and the west explores green innovation such as photovoltaic-distillation coupled systems. Technologically, MVR integration cuts unit water production energy consumption by 32.4%; intelligent sensor penetration hits 41.7%, and digital twin operation and maintenance is piloted in key biopharmaceutical projects.
